Aug 19, 2024, 09:57
3rd line treatments in pancreatic cancer
Erman Akkus, Medical Oncology Fellow at Ankara University, shared a post on X about a recent paper by A. Gueiderikh et al. published in BMC Cancer.
“Pancreatic adenocarcinoma third line systemic treatments: a retrospective cohort study”
Authors: Gueiderikh, A., Tarabay, A., Abdelouahab, M. et al.
“3rd line treatments in pancreatic cancer
- 37% of patients could proceed to 3rd line
- mOFS: 2 mo, mOS:5.5 mo
- Erlotinib and gemcitabine monotherapy -> negative outcomes.”
Source: Erman Akkus/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 21, 2024, 06:49
Nov 20, 2024, 20:38
Nov 20, 2024, 20:27
Nov 20, 2024, 19:12
Nov 20, 2024, 19:12